search
Back to results

Examining the Feasibility of Prolonged Ketone Concentrate Supplement Drink Consumption in Adults With Type 2 Diabetes

Primary Purpose

Diabetes Mellitus, Type 2, Hyperglycemia, Ketosis

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Dietary Supplement: D-β-hydroxybutyric acid with R-1,3-butanediol
Inert placebo
Sponsored by
University of British Columbia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

30 Years - 69 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: diagnosed with type 2 diabetes by a physician at least 1 year prior stable use of glucose-lowering medications for at least three months must be able to read and understand English in order to complete the study questionnaires Exclusion Criteria: competitively trained endurance athlete actively attempting to gain or lose weight having a history of mental illness or existing neurological disease having a history of cardiovascular events in the last two years, hypoglycemia, irritable bowel syndrome, or inflammatory bowel disease are currently taking SGLT2 inhibitors or insulin are using more than 2 classes of glucose-lowering medication currently following a ketogenic diet or regularly taking ketone supplements unable to commit to a 90-day trial being unable to follow remote guidance by internet or smartphone currently taking natural or over-the-counter supplements specifically designed to lower blood glucose (e.g., berberine, bitter melon)

Sites / Locations

  • University of British Columbia OkanaganRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Experimental: Exogenous Ketone Supplement

Placebo Comparator: Inert placebo

Arm Description

Participants will be instructed to consume a total of 177 mL of the exogenous ketone supplement drink (for a total of 30 g of beta-hydroxybutyrate) per day (3 doses at 59 mL containing 10 g of beta-hydroxybutyrate each) for a period of 90 days.

Participants will be instructed to consume an equivalent volume (177 mL) of taste- and volume-matched placebo per day (3 doses at 59 mL) for 90 days.

Outcomes

Primary Outcome Measures

To determine the feasibility of conducting a randomized controlled trial (RCT) on the effects of consumption of a ketone supplement in adults with type 2 diabetes in free-living environment for 90 days: Recruitment rate of participants into the trial
A recruitment rate of at least 4 participants per month (which will ensure the study is fully enrolled within a 1-year timeline) will be acceptable.
To determine the feasibility of conducting such an RCT: Compliance as measured by the self-reported volume of ketone supplement drink consumed
≥ 67% of the drinks provided being consumed by participants as determined via self-report (i.e., an average of two out of three drinks per day being consumed) will be acceptable.
To determine the feasibility of conducting such an RCT: Retention as measured by the number of participants that complete the study
≤ 30% of recruited participants dropping out of the study will be acceptable

Secondary Outcome Measures

Measures of glycemic control (HbA1c)
Glycemic control will be measured by assessing HbA1c in a clinical laboratory.
Measures of glycemic control (postprandial glucose area under the curve)
Glycemic control will be measured by continuous glucose monitoring using the FreeStyle Libre 2 (Abbott) and quantified by assessing 2-hour postprandial hyperglycemia.
Measures of glycemic control (average daily glucose)
Glycemic control will be measured by continuous glucose monitoring using the FreeStyle Libre 2 (Abbott) and quantified by assessing the average daily glucose.
Measures of glycemic control (glucose variability)
Glycemic control will be measured by continuous glucose monitoring using the FreeStyle Libre 2 (Abbott) and quantified by assessing glucose variability.
Supplement acceptability
Supplement acceptability will be assessed via questionnaire.
Gastrointestinal distress
Gastrointestinal distress will be assessed via questionnaire.
Self-reported body weight
Self-reported body weight will be assessed by questionnaire.
Self-reported waist circumference
Self-reported waist circumference will be assessed by questionnaire (using study-provided measurement tape).
Self-reported energy consumption
Self-reported energy consumption will be assessed via 24-hour dietary recalls.
Levels of perceived hunger
Levels of perceived hunger will be assessed via questionnaire.
High-sensitivity c-reactive protein
High-sensitivity c-reactive protein will be measured in a clinical laboratory.
Hematology panel
Hematology panel will be measured in a clinical laboratory.
Liver enzymes (ALT, AST)
Liver enzymes (ALT, AST) will be measured in a clinical laboratory.
Lipid panel (triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, non-high density lipoprotein cholesterol, cholesterol/high-density lipoprotein cholesterol ratio)
Lipid panel will be measured in a clinical laboratory.
Levels of physical activity
Theory of planned behaviour will be assessed via questionnaire.
Sleep quality
Sleep quality will be assessed via questionnaire.
Cravings
Cravings will be assessed via questionnaire.
Self-rated health
Self-rated health and its impacts on daily life will be assessed via questionnaire.
Self-reported blood pressure (systolic and diastolic)
Self-reported blood pressure (systolic and diastolic) will be assessed via questionnaire (via study-provided blood pressure monitors).
Theory of planned behaviour
Theory of planned behaviour will be assessed via questionnaire.
Overall acceptability
Will be assessed via an open ended questionnaire either at completion time or in case of withdrawal

Full Information

First Posted
July 4, 2023
Last Updated
August 1, 2023
Sponsor
University of British Columbia
search

1. Study Identification

Unique Protocol Identification Number
NCT05983562
Brief Title
Examining the Feasibility of Prolonged Ketone Concentrate Supplement Drink Consumption in Adults With Type 2 Diabetes
Official Title
Examining the Feasibility of Prolonged Ketone Concentrate Supplement Drink Consumption in Adults With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 26, 2023 (Actual)
Primary Completion Date
November 30, 2023 (Anticipated)
Study Completion Date
November 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of British Columbia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Brief Summary: Ketones are a source of energy and signaling molecule that are produced by the body when not consuming any food or consistently eating a low-carbohydrate "keto" diet. Blood ketones can be used as a source of energy by the body, but they may also act as signals that impact how different cells in the body function. Recently, ketone supplements have been developed that can be consumed as a drink. These supplements can raise blood ketones without having to fast or eat a "keto" diet. Previous studies have shown that these supplement drinks can lower blood sugar without having to make any other dietary changes. Drinking these ketone supplements may therefore be an effective strategy to improve blood sugar control and influence how cells function. To find out if it is feasible for people with type 2 diabetes to drink these ketones supplements regularly over 90 days, we will compare between two groups in this study: one group that will be asked to drink ketone supplements, and one group that will be asked to drink a placebo supplement.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2, Hyperglycemia, Ketosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental: Exogenous Ketone Supplement
Arm Type
Experimental
Arm Description
Participants will be instructed to consume a total of 177 mL of the exogenous ketone supplement drink (for a total of 30 g of beta-hydroxybutyrate) per day (3 doses at 59 mL containing 10 g of beta-hydroxybutyrate each) for a period of 90 days.
Arm Title
Placebo Comparator: Inert placebo
Arm Type
Placebo Comparator
Arm Description
Participants will be instructed to consume an equivalent volume (177 mL) of taste- and volume-matched placebo per day (3 doses at 59 mL) for 90 days.
Intervention Type
Dietary Supplement
Intervention Name(s)
Dietary Supplement: D-β-hydroxybutyric acid with R-1,3-butanediol
Intervention Description
Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
Intervention Type
Other
Intervention Name(s)
Inert placebo
Intervention Description
Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively
Primary Outcome Measure Information:
Title
To determine the feasibility of conducting a randomized controlled trial (RCT) on the effects of consumption of a ketone supplement in adults with type 2 diabetes in free-living environment for 90 days: Recruitment rate of participants into the trial
Description
A recruitment rate of at least 4 participants per month (which will ensure the study is fully enrolled within a 1-year timeline) will be acceptable.
Time Frame
Start of enrolment to completion of enrolment
Title
To determine the feasibility of conducting such an RCT: Compliance as measured by the self-reported volume of ketone supplement drink consumed
Description
≥ 67% of the drinks provided being consumed by participants as determined via self-report (i.e., an average of two out of three drinks per day being consumed) will be acceptable.
Time Frame
Across the 90-day intervention period (days 0 through 90)
Title
To determine the feasibility of conducting such an RCT: Retention as measured by the number of participants that complete the study
Description
≤ 30% of recruited participants dropping out of the study will be acceptable
Time Frame
Across the 90-day intervention period (days 0 through 90)
Secondary Outcome Measure Information:
Title
Measures of glycemic control (HbA1c)
Description
Glycemic control will be measured by assessing HbA1c in a clinical laboratory.
Time Frame
Day 0 (pre-intervention/baseline) and day 90 (post-intervention/follow-up)
Title
Measures of glycemic control (postprandial glucose area under the curve)
Description
Glycemic control will be measured by continuous glucose monitoring using the FreeStyle Libre 2 (Abbott) and quantified by assessing 2-hour postprandial hyperglycemia.
Time Frame
Days -5 through 9 (5 days of baseline and first 9 days of intervention period) and days 77 through 90 (last 2 weeks)
Title
Measures of glycemic control (average daily glucose)
Description
Glycemic control will be measured by continuous glucose monitoring using the FreeStyle Libre 2 (Abbott) and quantified by assessing the average daily glucose.
Time Frame
Days -5 through 9 (5 days of baseline and first 9 days of intervention period) and days 77 through 90 (last 2 weeks)
Title
Measures of glycemic control (glucose variability)
Description
Glycemic control will be measured by continuous glucose monitoring using the FreeStyle Libre 2 (Abbott) and quantified by assessing glucose variability.
Time Frame
Days -5 through 9 (5 days of baseline and first 9 days of intervention period) and days 77 through 90 (last 2 weeks)
Title
Supplement acceptability
Description
Supplement acceptability will be assessed via questionnaire.
Time Frame
Days 1, 45, and 90
Title
Gastrointestinal distress
Description
Gastrointestinal distress will be assessed via questionnaire.
Time Frame
Days 1, 45, and 90
Title
Self-reported body weight
Description
Self-reported body weight will be assessed by questionnaire.
Time Frame
Day 0 (pre-intervention/baseline) and day 90 (post-intervention/follow-up)
Title
Self-reported waist circumference
Description
Self-reported waist circumference will be assessed by questionnaire (using study-provided measurement tape).
Time Frame
ay 0 (pre-intervention/baseline) and day 90 (post-intervention/follow-up)
Title
Self-reported energy consumption
Description
Self-reported energy consumption will be assessed via 24-hour dietary recalls.
Time Frame
Days 0 (pre-intervention/baseline), 45, and 90
Title
Levels of perceived hunger
Description
Levels of perceived hunger will be assessed via questionnaire.
Time Frame
Days 0 (pre-intervention/baseline), 45, and 90
Title
High-sensitivity c-reactive protein
Description
High-sensitivity c-reactive protein will be measured in a clinical laboratory.
Time Frame
Day 0 (pre-intervention/baseline) and day 90 (post-intervention/follow-up)
Title
Hematology panel
Description
Hematology panel will be measured in a clinical laboratory.
Time Frame
Day 0 (pre-intervention/baseline) and day 90 (post-intervention/follow-up)
Title
Liver enzymes (ALT, AST)
Description
Liver enzymes (ALT, AST) will be measured in a clinical laboratory.
Time Frame
Day 0 (pre-intervention/baseline) and day 90 (post-intervention/follow-up)
Title
Lipid panel (triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, non-high density lipoprotein cholesterol, cholesterol/high-density lipoprotein cholesterol ratio)
Description
Lipid panel will be measured in a clinical laboratory.
Time Frame
Day 0 (pre-intervention/baseline) and day 90 (post-intervention/follow-up)
Title
Levels of physical activity
Description
Theory of planned behaviour will be assessed via questionnaire.
Time Frame
Days 0 (pre-intervention/baseline) and 45
Title
Sleep quality
Description
Sleep quality will be assessed via questionnaire.
Time Frame
Days 0 (pre-intervention/baseline), 45, and 90
Title
Cravings
Description
Cravings will be assessed via questionnaire.
Time Frame
Days 0 (pre-intervention/baseline), 45, and 90
Title
Self-rated health
Description
Self-rated health and its impacts on daily life will be assessed via questionnaire.
Time Frame
Days 0 (pre-intervention/baseline), 45, and 90
Title
Self-reported blood pressure (systolic and diastolic)
Description
Self-reported blood pressure (systolic and diastolic) will be assessed via questionnaire (via study-provided blood pressure monitors).
Time Frame
Days 0 (pre-intervention/baseline), 45, and 90
Title
Theory of planned behaviour
Description
Theory of planned behaviour will be assessed via questionnaire.
Time Frame
Days 0 (pre-intervention/baseline) and 45
Title
Overall acceptability
Description
Will be assessed via an open ended questionnaire either at completion time or in case of withdrawal
Time Frame
Day 90 or in case of withdrawal

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: diagnosed with type 2 diabetes by a physician at least 1 year prior stable use of glucose-lowering medications for at least three months must be able to read and understand English in order to complete the study questionnaires Exclusion Criteria: competitively trained endurance athlete actively attempting to gain or lose weight having a history of mental illness or existing neurological disease having a history of cardiovascular events in the last two years, hypoglycemia, irritable bowel syndrome, or inflammatory bowel disease are currently taking SGLT2 inhibitors or insulin are using more than 2 classes of glucose-lowering medication currently following a ketogenic diet or regularly taking ketone supplements unable to commit to a 90-day trial being unable to follow remote guidance by internet or smartphone currently taking natural or over-the-counter supplements specifically designed to lower blood glucose (e.g., berberine, bitter melon)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jonathan Little, PhD
Phone
250-807-9876
Email
jonathan.little@ubc.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Juan Pablo Tortoriello, MD
Phone
250-864-2003
Email
jptorto@mail.ubc.ca
Facility Information:
Facility Name
University of British Columbia Okanagan
City
Kelowna
State/Province
British Columbia
ZIP/Postal Code
V1V 1V7
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jonathan P Little
Phone
2508079876
Email
jonathan.little@ubc.ca

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The investigators will share individual patient data (de-identified) with researchers upon reasonable request.
IPD Sharing Time Frame
The de-identified data and associated documents will be made available to researchers upon reasonable request for the duration that is required by the researchers.
IPD Sharing Access Criteria
Researchers from accredited institutions will be granted access to the de-identified data and associated documents provided they can show that it will be used for a research-related purpose (e.g., meta-analysis).

Learn more about this trial

Examining the Feasibility of Prolonged Ketone Concentrate Supplement Drink Consumption in Adults With Type 2 Diabetes

We'll reach out to this number within 24 hrs